3 news items
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
PPBT
14 Mar 24
that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
PPBT
5 Mar 24
factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
PPBT
27 Feb 24
-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies
- Prev
- 1
- Next